RT Journal Article
SR Electronic
T1 UV-A and UV-B Can Neutralize SARS-CoV-2 Infectivity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.28.21257989
DO 10.1101/2021.05.28.21257989
A1 Biasin, Mara
A1 Strizzi, Sergio
A1 Bianco, Andrea
A1 Macchi, Alberto
A1 Utyro, Olga
A1 Pareschi, Giovanni
A1 Loffreda, Alessia
A1 Cavalleri, Adalberto
A1 Lualdi, Manuela
A1 Trabattoni, Daria
A1 Tacchetti, Carlo
A1 Mazza, Davide
A1 Clerici, Mario
YR 2021
UL http://medrxiv.org/content/early/2021/05/31/2021.05.28.21257989.abstract
AB We performed an in-depth analysis of the virucidal effect of discrete wavelengths: UV-C (278 nm), UV-B (308 nm), UV-A (366 nm) and violet (405 nm) on SARS-CoV-2. By using a highly infectious titer of SARS-CoV-2 we observed that the violet light-dose resulting in a 2-log viral inactivation is only 10−4 times less efficient than UV-C light. Moreover, by qPCR and fluorescence in situ hybridization (FISH) approach we verified that the viral titer typically found in the sputum of COVID-19 patients can be completely inactivated by the long UV-wavelengths corresponding to UV-A and UV-B solar irradiation. The comparison of the UV action spectrum on SARS-CoV-2 to previous results obtained on other pathogens suggests that RNA viruses might be particularly sensitive to long UV wavelengths. Our data extend previous results showing that SARS-CoV-2 is highly susceptible to UV light and offer an explanation to the reduced incidence of SARS-CoV-2 infection seen in the summer season.SYNOPSIS UV-A, UV-B and violet wavelengths kill SARS-CoV-2, supporting the sterilizing effects of the solar pump on human pathogens and the explanation of the seasonality of the COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThese experiments were supported by the following grants: Bando Regione Lombardia DG Welfare cod. RL_DG-WEL20MBIAS_01 CARIPLO EXTRABANDO E PROGETTI TERRITORIALI cod. CAR_EXT20MBIAS_01, Progetto Regione Lombardia. POR FESR 2014‐2020. AZIONE I.1.B.1.3 Artificial Intelligence Sars Covid Risk Evaluation(AI-SCoRE) to CT; and by INAF in the context of the initiatives triggered by the Italian Ministero Universita e della Ricerca (MUR) to counter the COVID19 pandemic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Milano, Milan, Italy Italian National Institute for Astrophysics, Italy IRCCS Ospedale San Raffaele, Milan, Italy IRCCS Foundation, Istituto Nazionale dei Tumori, Milan, Italy Don C. Gnocchi Foundation, IRCCS Foundation, Milan, ItalyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are published in the manuscript